|1.||Lin, Topp: 1 article (03/2008)|
|2.||Tan, Yi-Hung: 1 article (03/2008)|
|3.||Sun, Ying-Chieh: 1 article (03/2008)|
|4.||Juan, Hsueh-Fen: 1 article (03/2008)|
|5.||Hsieh-Li, Hsiu Mei: 1 article (03/2008)|
|6.||Wang, Yi-Ching: 1 article (03/2008)|
|7.||Lee, Kung-Hsueh: 1 article (03/2008)|
|8.||Wu, Xuli: 1 article (04/2006)|
|9.||Chen, Ching-Shih: 1 article (04/2006)|
|10.||Tong, Zhimin: 1 article (04/2006)|
|1.||Lung Neoplasms (Lung Cancer)
03/15/2008 - "Our molecular and proteomic results show the potential of OSU03013 as an anticancer drug for lung cancer."
03/15/2008 - "Our results indicated that OSU03013 had low-dose (1 approximately 4 microM) cytotoxicity in all lung cancer cell lines tested 48 hours posttreatment. "
03/15/2008 - "Cytotoxicity and proteomics analyses of OSU03013 in lung cancer."
04/01/2006 - "The aim of the present studies was to investigate the potential of a celecoxib-derived PDK1 inhibitor (OSU03013), that does not inhibit cyclooxygenase-2, to kill lung cancer cells in vitro. "
03/15/2008 - "In order to investigate whether OSU03013, a derivative of celecoxib, can be a potential drug for lung cancer treatment, we examined its cytotoxicity mechanisms by flow cytometry and phosphatidylserine staining in A549, CL1-1, and H1435 lung cancer cell lines, which are resistant to the conventional drug, cisplatin. "
|2.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
|2.||Cyclooxygenase 2 (Cyclooxygenase-2)
|4.||Glycogen Synthase Kinases
|5.||Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)